Search

Your search keyword '"Nakamura, Motonobu"' showing total 1,103 results
Start Over Author "Nakamura, Motonobu"
1,103 results on '"Nakamura, Motonobu"'

2. J‐AVENUE: A retrospective, real‐world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first‐line maintenance therapy in Japan

Author

Kikuchi, Eiji, primary, Hayakawa, Nozomi, additional, Nakayama, Masashi, additional, Uno, Masahiro, additional, Nakatsu, Hiroomi, additional, Kitagawa, Chiyoe, additional, Miyake, Hideaki, additional, Yamada, Takeshi, additional, Fujita, Kazutoshi, additional, Shimoyama, Hideaki, additional, Nishihara, Kiyoaki, additional, Kobayashi, Mizuki, additional, Nakamura, Motonobu, additional, Fujimoto, Kiyohide, additional, Sano, Takeshi, additional, Nishiyama, Naotaka, additional, Ito, Takayuki, additional, Kajita, Masahiro, additional, Kobayashi, Takashi, additional, and Kitamura, Hiroshi, additional

Published
2024
Full Text
View/download PDF

4. Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study

Author

Minato, Akinori, primary, Furubayashi, Nobuki, additional, Nagata, Yujiro, additional, Tomoda, Toshihisa, additional, Masaoka, Hiroyuki, additional, Song, Yoohyun, additional, Hori, Yoshifumi, additional, Kiyoshima, Keijiro, additional, Negishi, Takahito, additional, Kuroiwa, Kentaro, additional, Seki, Narihito, additional, Tomisaki, Ikko, additional, Harada, Kenichi, additional, Nakamura, Motonobu, additional, and Fujimoto, Naohiro, additional

Published
2024
Full Text
View/download PDF

6. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Author

Park, Se Hoon, van der Heijden, Michiel S., Necchi, Andrea, Castellano, Daniel, Bamias, Aristotelis, Lee, Jae Lyun, De Giorgi, Ugo, Bögemann, Martin, Eigl, Bernhard J., Tsiatas, Marinos, Powles, Thomas, Novikov, Andrey, Skoneczna, Iwona, Mukherjee, Som D., Suarez, Cristina, Westgeest, Hans, Fradet, Yves, Flechon, Aude, Ou, Yen-Chuan, Park, Inkeun, Matveev, Vsevolod, Pérez-Valderrama, Begoña, Cheng, Susanna, Frank, Stephen, Gurney, Howard, Anido, Urbano, Hamzaj, Alketa, Retz, Margitta, Sridhar, Srikala, Scagliotti, Giorgio Vittorio, Voortman, Jens, Alekseev, Boris, Alyasova, Anna, Komyakov, Boris, Dumez, Herlinde, Pavic, Michel, Kimura, Go, Mizokami, Atsushi, Osanto, Susanne, Arranz, Jose Angel, Piersma, Djura, Shin, Sang Joon, Karyakin, Oleg, Delgado, Ignacio, Gonzalez, Jose Luis, Pang, See-Tong, Tran, Anna, Lipatov, Oleg, Su, Wen-Pin, Flaig, Thomas, Alva, Ajjai, Park Kyong, Hwa, Kopyltsov, Evgeny, Almagro, Elena, Domenech, Monserrat, Chang, Yen-Hwa, Sautois, Brieuc, Ravaux, Andre, Aravantinos, Gerasimos, Georgoulias, Vasileios, Mulder, Sasja, Kim, Yu Jung, Kater, Fabio, Chevreau, Christine, Tagawa, Scott, Zalewski, Pawel, Joly, Florence, Loriot, Yohann, Hatiboglu, Gencay, Gianni, Luca, Morelli, Franco, Tambaro, Rosa, Hashimoto, Yasuhiro, Nosov, Alexander, Font, Albert, Rodriguez-Vida, Alejo M., Jones, Robert, Vasudev, Naveen, Srinivas, Sandhya, Zhang, Jingsong, Gil, Thierry, Finch, Daygen, Grimm, Marc-Oliver, Su, Yu-Li, Chowdhury, Simon, Hocking, Christopher, Plas, Eugen, North, Scott, Jensen, Niels Viggo, Theodore, Christine, Imkamp, Florian, Peer, Avivit, Kobayashi, Takashi, Sakai, Hideki, Sassa, Naoto, Yoshimura, Kazuhiro, Aarts, Maureen, Ferreira Castro, Ana, Topuzov, Marlen, Rodriguez, Juan Francisco, Vazquez, Federico Jose, Tsai, Yu-Chieh, Crabb, Simon, Hussain, Syed, Bendell, Johanna, Gross-Goupil, Marine, Gwenaelle, Gravis, Berger, Raanan, Statsenko, Galina, Evans, Linda, Drakaki, Alexandra, Somer, Bradley, Davis, Ian, Lynam, James, Borges, Giuliano, Dettino, Aldo, Fay, André P., Martins, Graziella, Zucca, Luis Eduardo, Agerbaek, Mads, Kalofonos, Haralambos, Rosenbaum, Eli, Enokida, Hideki, Kikukawa, Hiroaki, Nishimura, Kazuo, Tamada, Satoshi, Uemura, Motohide, Lopez, Yamil, Gietema, Jourik, Slojewski, Marcin, Fernandes, Isabel, Smolin, Alexey, Mazhar, Danish, Kalebasty, Arash Rezazadeh, Carthon, Bradley, Loidl, Wolfgang, Franke, Fabio, Girotto, Gustavo, Alimohamed, Nimira, Macfarlane, Robyn, Pappot, Helle, Niegisch, Guenter, Mavroudis, Dimitrios, Sella, Avishay, Porta, Camillo, Ebara, Shin, Nakamura, Motonobu, Obara, Wataru, Okuno, Norihiko, Shinohara, Nobuo, Sugimoto, Mikio, Suzuki, Akitaka, Tokuda, Noriaki, Uemura, Hiroji, Yamaguchi, Akito, Ramirez, Francisco, Rozanowski, Pawel, Wiechno, Pawel, Keam, Bhumsuk, Kislov, Nikolay, Plaksin, Denis, Cicin, Irfan, Kumar, Satish, Galsky, Matthew D., Petrylak, Daniel P., Rosales, Joseph, Vaishampayan, Ulka, Culine, Stephane, Papandreou, Christos, Nara, Taketoshi, Erman, Mustafa, Kreiger, Laurence, Janoski, Juliana, Rosa, Diogo, Siqueira, Mariana, Canil, Christina, Sengelov, Lisa, Tourani, Jean-Marc, Arai, Gaku, Hashine, Katsuyoshi, Kawakita, Mutsushi, Nakaigawa, Noboru, Nomi, Hayahito, Shiina, Hiroaki, Suzuki, Hiroyoshi, Yonese, Junji, Kuri, Roberto, Macedo, Eleazar, Rivera, Samuel, Villalobos Prieto, Alberto, Polakiewicz-Gilowska, Anna, Zaucha, Renata, Lopes, Fabio, Ponomarev, Roman, Pomerantz, Mark, Shariat, Shahrokh, Luk, Cynthia, Lesniewski-Kmak, Krzysztof, van der Heijden, Michiel S, Galsky, Matthew D, Petrylak, Daniel P, Ogawa, Osamu, Lee, Jae-Lyun, Eigl, Bernhard J, Mukherjee, Som D, Suárez, Cristina, Fay, André P, Duran, Ignacio, Wildsmith, Sophie, He, Philip, Angra, Natasha, Gupta, Ashok K, Levin, Wendy, and Bellmunt, Joaquim

Published
2020
Full Text
View/download PDF

7. Metastatic castration resistant prostate cancer patients' experience with Radium-223 treatment in Japan.

Author

Akakura, Koichiro, Uemura, Hiroji, Kawakami, Satoru, Yokomizo, Akira, Nakamura, Motonobu, Nishimura, Kazuo, Komori, Tetsushi, and Ledesma, Dianne Athene

Abstract

Aim: We aimed to determine Japanese metastatic castration resistant prostate cancer (CRPC) patients' Ra-223 treatment experience. Patients & methods: Patients answered the Cancer Therapy Satisfaction Questionnaire (CTSQ domains: Satisfaction with Therapy [SWT], Expectations of Therapy [ET], Feelings about Side Effects [FSE]), the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) and the FACT-Bone Pain (FACT-BP) Questionnaire at baseline, during (vists 3 and 5) and after treatment (end of observation; EOO). Results: Data from 72 patients were included. Baseline median CTSQ scores SWT: 66.1 (IQR19.7), ET: 75.0 (IQR45), and FSE 68.8 (IQR 34.4) were unchanged during vists 3 and 5, but the SWT (-3.57 [IQR17.9]) and ET (-5.0 [IQR30]) decreased while FSE was unchanged (0.0 [IQR31.25]) at EOO. The median MAX-PC (18.0 [IQR 49]) score was unchanged (0.0, IQR 6) while the median FACT BP (54.0 [IQR13]) score decreased by -1.0 (IQR 8) at EOO. Conclusion: Japanese metastatic castration resistant prostate cancer patients' experience is stable during Ra-223 treatment. We wanted to know the treatment experience with Radium-223 (Ra-223) among Japanese prostate cancer patients. Ra-223 is a radioactive molecule used for the treatment of metastatic castration resistant prostate cancer. We asked patients to answer different questionnaires on treatment satisfaction, anxiety and quality of life before, during, and after treatment with Ra-223. Based on the patients' answers to our questionnaires, treatment satisfaction, anxiety and quality of life remain stable while the patients undergo treatment with Ra-223, but in some aspects may decline after treatment. The results mean that patients' experience during Ra-223 treatment is stable but patients should share any concerns they have about their treatment with their doctors. A study on Japanese metastatic castration resistant prostate cancer patients who receive Radium-223 therapy showed that treatment satisfaction, anxiety and health-related quality of life remain stable among patients while undergoing Ra-223 treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study

Author

Matsubara, Nobuaki, Kimura, Go, Uemura, Hiroji, Uemura, Hirotsugu, Nakamura, Motonobu, Nagamori, Satoshi, Mizokami, Atsushi, Kikukawa, Hiroaki, Hosono, Makoto, Kinuya, Seigo, Krissel, Heiko, Siegel, Jonathan, and Kakehi, Yoshiyuki

Published
2020
Full Text
View/download PDF

15. Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study

Author

FURUBAYASHI, NOBUKI, primary, MINATO, AKINORI, additional, NEGISHI, TAKAHITO, additional, SAKAMOTO, NAOTAKA, additional, SONG, YOOHYUN, additional, HORI, YOSHIFUMI, additional, TOMODA, TOSHIHISA, additional, MASAOKA, HIROYUKI, additional, HARADA, MIRII, additional, TAMURA, SHINGO, additional, KOBAYASHI, HIROKI, additional, MORIHARA, KAEDE, additional, KUROIWA, KENTARO, additional, SEKI, NARIHITO, additional, FUJIMOTO, NAOHIRO, additional, and NAKAMURA, MOTONOBU, additional

Published
2023
Full Text
View/download PDF

19. Efficacy and safety of third- and fourth-line targeted therapy in japanese patients with metastatic renal cell carcinoma: A retrospective analysis

Author

Negishi Takahito, Nagase Kei, Iwai Hidenori, Furubayashi Nobuki, Taguchi Kenichi, and Nakamura Motonobu

Subjects
Diseases of the genitourinary system. Urology, RC870-923
Abstract

Introduction: There is limited data on the efficacy of sequential targeted therapy for metastatic renal cell carcinoma (mRCC) beyond the second line, especially for Asian patients. We evaluated the efficacy and side effects of targeted therapy beyond the second line. Materials and Methods: We retrospectively reviewed 69 patients who were administered targeted therapy for mRCC at our institution between 2008 and 2016. Sunitinib, pazopanib, sorafenib, axitinib, everolimus, and temsirolimus were available in Japan in 2016, and treatment had been conducted with those six agents. Twenty-four patients underwent therapy beyond the second line. The progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. In addition, a survey on patients' attitudes toward cancer treatment was conducted. Twenty-five of the 69 patients responded to the question with their opinions on the continuation of treatment after standard therapy failure. Results: The median PFS was 7.6 and 2.5 months for third- and fourth-line therapy. The median OS calculated from the initiation of third-line therapy was 14.2 months. The rates of serious toxicities with third- and fourth-line regimens were not markedly increased compared with first- and second-line therapies. Forty percent of patients hoped to continue treatment after exhausting standard care. Conclusions: Our retrospective study indicates the efficacy and safety of third- and fourth-line targeted therapies. In addition to the efficacy, a patient can also influence treatment continuation.

Published
2018
Full Text
View/download PDF

20. Bone‐modifying agents are protective for symptomatic skeletal events in Radium‐223 treatment.

Author

Blas, Leandro, Shiota, Masaki, Matsumoto, Takashi, Hori, Yoshifumi, Nakamura, Motonobu, Seki, Narihito, Kuroiwa, Kentaro, Yokomizo, Akira, Morokuma, Futoshi, Kiyoshima, Keijiro, and Eto, Masatoshi

Subjects
CASTRATION-resistant prostate cancer, PROSTATE cancer patients, BONE metastasis, SPONTANEOUS fractures, LOG-rank test
Abstract

Introduction: Radium‐223 (Ra‐223) dichloride therapy increases overall survival and delays time to the first symptomatic skeletal event (SSE) in patients with castration‐resistant prostate cancer (CRPC) and bone metastases. Bone‐modifying agents (BMA) reduce SSE in patients with bone metastasis, but there is little information on their use with Ra‐223. This study aimed to investigate the effect of BMA on SSE in patients with bone metastatic CRPC treated with Ra‐223 in real‐world practice. Methods: We included 73 patients treated with Ra‐223 from 10 institutions in Japan. Time to the first SSE was estimated using the Kaplan–Meier method and compared between groups using the log‐rank test. We used univariate analysis to ascertain the association between variables and SSE. Results: During a median follow‐up of 12.7 months (interquartile range, 7–21.7), 12 (16.4%) patients presented SSE. Age and BMA use were different between men with and without SSE. The 1‐year SSE‐free survival rate from Ra‐223 treatment initiation was 82.4% (95% CI, 69.4%–90.2%). BMA use was associated with favorable SSE‐free survival (hazard risk, 0.23; 95% confidence interval, 0.061–0.85; p = 0.027). Two (4.7%) and seven (23.3%) patients presented symptomatic pathological bone fracture in groups with and without BMA use, respectively (p = 0.017). Conclusion: This study stresses the importance of BMA use in patients with CRPC and bone metastases in Ra‐223 treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Paralytic Ileus During Treatment of Pulmonary and Renal Tuberculosis in a Non-Human Immunodeficiency Virus Patient: An Unusual Presentation of Tuberculosis-immune Reconstitution Inflammatory Syndrome

Author

Hashiba, Toyohiro, primary, Sugahara, Mai, additional, Ota, Yui, additional, Kaseda, Ken, additional, Kashiwagi, Yusuke, additional, Nakamura, Motonobu, additional, Shinohara, Takayuki, additional, Ikeda, Mahoko, additional, Okugawa, Shu, additional, Sugimoto, Kazuma, additional, Sasaki, Kenichi, additional, Hamasaki, Yoshifumi, additional, Yamada, Daisuke, additional, Kume, Haruki, additional, Moriya, Kyoji, additional, and Nangaku, Masaomi, additional

Published
2023
Full Text
View/download PDF

28. Allergies

Author

Nakamura, Motonobu, Noiri, Eisei, editor, and Hanafusa, Norio, editor

Published
2014
Full Text
View/download PDF

34. The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status

Author

Furubayashi, Nobuki, primary, Minato, Akinori, additional, Negishi, Takahito, additional, Sakamoto, Naotaka, additional, Song, Yoohyun, additional, Hori, Yoshifumi, additional, Tomoda, Toshihisa, additional, Harada, Mirii, additional, Tamura, Shingo, additional, Kobayashi, Hiroki, additional, Wada, Yamato, additional, Kuroiwa, Kentaro, additional, Seki, Narihito, additional, Fujimoto, Naohiro, additional, and Nakamura, Motonobu, additional

Published
2022
Full Text
View/download PDF

35. Effectiveness and safety of radium‐223 dichloride in patients with castration‐resistant prostate cancer and bone metastases in real‐world practice: A multi‐institutional study

Author

Matsumoto, Takashi, primary, Hori, Yoshifumi, additional, Shiota, Masaki, additional, Blas, Leandro, additional, Nakamura, Motonobu, additional, Seki, Narihito, additional, Kuroiwa, Kentaro, additional, Yokomizo, Akira, additional, Morokuma, Futoshi, additional, Kiyoshima, Keijiro, additional, and Eto, Masatoshi, additional

Published
2022
Full Text
View/download PDF

38. Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors

Author

Negishi, Takahito, primary, Nakagawa, Tohru, additional, Nishiyama, Naotaka, additional, Kitamura, Hiroshi, additional, Okajima, Eijiro, additional, Furubayashi, Nobuki, additional, Hori, Yoshifumi, additional, Kuroiwa, Kentarou, additional, Son, Yuhyon, additional, Seki, Narihito, additional, Tomoda, Toshihisa, additional, and Nakamura, Motonobu, additional

Published
2022
Full Text
View/download PDF

43. Peritoneal Dialysis-Related Peritonitis Caused by Streptococcus oralis

Author

Kotani, Akihiro, Oda, Yasuhiro, Hirakawa, Yosuke, Nakamura, Motonobu, Hamasaki, Yoshifumi, and Nangaku, Masaomi

Subjects
Male, peritoneal dialysis, Peritoneal Dialysis, Continuous Ambulatory, Humans, Case Report, Streptococcus oralis, Peritonitis, peritoneal dialysis-related peritonitis, infection, viridans group streptococci, Aged, Anti-Bacterial Agents
Abstract

A 77-year-old man developed peritoneal dialysis-related peritonitis caused by Streptococcus oralis, a rare pathogen causing the disease. The infection, which was not controlled by one-week intraperitoneal administration of cefazolin and ceftazidime, was cured only after switching to two-week intravenous administration of cefazolin and ceftazidime. The patient had no major dental disease or recent history of dental intervention. This case suggests that S. oralis might cause peritoneal dialysis-related peritonitis with persistent systemic inflammation via an extra-oral infection route. The clinical course is discussed along with a review of the literature.

Published
2021

49. Involvement of activation-induced cytidine deaminase in skin cancer development

Author

Nonaka, Taichiro, Toda, Yoshinobu, Hiai, Hiroshi, Uemura, Munehiro, Nakamura, Motonobu, Yamamoto, Norio, Asato, Ryo, Hattori, Yukari, Bessho, Kazuhisa, Minato, Nagahiro, and Kinoshita, Kazuo

Subjects
Skin cancer -- Genetic aspects -- Development and progression, Hydrolases -- Properties, Squamous cell carcinoma -- Genetic aspects -- Development and progression, Enzymes -- Properties, Molecular targeted therapy -- Innovations, Health care industry
Abstract

Most skin cancers develop as the result of UV light-induced DNA damage; however, a substantial number of cases appear to occur independently of UV damage. A causal link between UV-independent skin cancers and chronic inflammation has been suspected, although the precise mechanism underlying this association is unclear. Here, we have proposed that activation-induced cytidine deaminase (AID, encoded by AICDA) links chronic inflammation and skin cancer. We demonstrated that Tg mice expressing AID in the skin spontaneously developed skin squamous cell carcinoma with Hras and Trp53 mutations. Furthermore, genetic deletion of Aicda reduced tumor incidence in a murine model of chemical-induced skin carcinogenesis. AID was expressed in human primary keratinocytes in an inflammatory stimulus-dependent manner and was detectable in human skin cancers. Together, the results of this study indicate that inflammation-induced AID expression promotes skin cancer development independently of UV damage and suggest AID as a potential target for skin cancer therapeutics., Introduction Cancer development involves a cascade of genetic alterations that activate oncogenes and inactivate tumor-suppressor genes (1). Some genetic alterations are caused by external factors such as UV light, ionizing [...]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results